• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NICE Posts Upbeat Earnings, Joins FTI Consulting, NVIDIA, Moderna And Other Big Stocks Moving Higher On Thursday

    2/22/24 11:33:12 AM ET
    $ACVA
    $ALTI
    $AMD
    $AMLX
    Real Estate
    Real Estate
    Investment Managers
    Finance
    Get the next $ACVA alert in real time by email

    U.S. stocks were higher, with the Nasdaq Composite gaining more 2% on Thursday.

    Shares of NICE Ltd. (NASDAQ:NICE) rose sharply during Thursday’s session after the company reported better-than-expected fourth-quarter financial results and issued FY24 guidance above estimates.

    NICE reported fourth-quarter fiscal 2023 revenue growth of 9.6% year-over-year to $623.19 million, beating the consensus of $618.51 million. Adjusted EPS improved to $2.36 compared to $2.04 in the prior year, beating the consensus of $2.28.

    NICE shares jumped 10.4% to $249.39 on Thursday.

    Here are some other big stocks recording gains in today’s session.

    • Root, Inc. (NASDAQ:ROOT) shares shares rose 40.8% to $12.21 after posting better-than-expected fourth-quarter results.
    • Novavax, Inc. (NASDAQ:NVAX) gained 34.7% to $5.36. Novavax has reached a settlement related to the 2021 advance purchase agreement for Novavax's prototype Covid-19 vaccine (NVX-COV2373).
    • Mativ Holdings, Inc. (NYSE:MATV) climbed 27.6% to $15.00 following upbeat earnings.
    • Outset Medical, Inc. (NASDAQ:OM) rose 26% to $4.0680 following upbeat results.
    • Ocular Therapeutix, Inc. (NASDAQ:OCUL) climbed 22.2% to $9.19 after announcing a $325.0 million private placement.
    • Remitly Global, Inc. (NASDAQ:RELY) shares gained 19.5% to $21.13 after the company reported better-than-expected fourth-quarter financial results.
    • B. Riley Financial, Inc. (NASDAQ:RILY) climbed 19.3% to $18.13. B. Riley’s board issued a statement regarding internal review.
    • Super Micro Computer, Inc. (NASDAQ:SMCI) gained 19.2% to $875.07. Supermicro announced a proposed offering of $1.5 billion of convertible senior notes due 2029.
    • AlTi Global, Inc. (NASDAQ:ALTI) jumped 18.6% to $6.90. AlTi Global announced a strategic investment of up to $450 million by Allianz X and Constellation Wealth Capital.
    • Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) gained 17.5% to $18.00 following strong sales results.
    • ACV Auctions Inc. (NASDAQ:ACVA) rose 16.9% to $16.37 after the company reported better-than-expected fourth-quarter financial results and announced the settlement of its antitrust litigation related to the AutoIMS technology platform.
    • FTI Consulting, Inc. (NYSE:FCN) climbed 15.5% to $219.72 following upbeat results.
    • NVIDIA Corporation (NASDAQ:NVDA) gained 15.4% to $778.61 after the company reported better-than-expected fourth-quarter financial results and issued strong revenue guidance for the first quarter.
    • OUTFRONT Media Inc. (NYSE:OUT) climbed 15.4% to $14.35 following upbeat results.
    • Lantheus Holdings, Inc. (NASDAQ:LNTH) gained 14.4% to $64.90 following strong results.
    • Indivior PLC (NASDAQ:INDV) rose 13.3% to $19.83 following fourth-quarter results.
    • Installed Building Products, Inc. (NYSE:IBP) gained 12.8% to $228.59 after the company reported better-than-expected fourth-quarter financial results and authorized a $300 million stock repurchase program.
    • ICON Public Limited Company (NASDAQ:ICLR) rose 12.1% to $319.05 after the company reported better-than-expected fourth-quarter adjusted EPS results and issued FY24 guidance.
    • Celestica Inc. (NYSE:CLS) climbed 11.6% to $41.51.
    • Advanced Micro Devices, Inc. (NASDAQ:AMD) rose 11.6% to $183.27 in sympathy with NVIDIA, which reported better-than-expected quarterly financial results and issued revenue guidance above estimates.
    • Quanta Services, Inc. (NYSE:PWR) gained 11% to $234.42 after the company reported better-than-expected quarterly financial results and issued guidance.
    • Synopsys, Inc. (NASDAQ:SNPS) climbed 10.7% to $601.93 after the company reported better-than-expected first-quarter adjusted EPS results and issued strong guidance.
    • Q2 Holdings, Inc. (NASDAQ:QTWO) gained 9.5% to $45.82 following strong results.
    • Moderna, Inc. (NASDAQ:MRNA) gained 9.5% to $95.93 after the company reported fourth-quarter financial results.
    • Dell Technologies Inc. (NYSE:DELL) rose 8.7% to $88.46.
    • Wingstop Inc. (NASDAQ:WING) gained 8.4% to $336.34. Wingstop reported better-than-expected results for its fourth quarter on Wednesday.
    • Royal Caribbean Cruises Ltd. (NYSE:RCL) surged 7.9% to $124.00 after the company raised its FY24 adjusted EPS guidance. Also, the company said demand and bookings has exceeded expectations.
    • DigitalOcean Holdings, Inc. (NYSE:DOCN) rose 6.8% to $38.29 following upbeat results.

     

    Now Read This: Jim Cramer: Unity Software 'Had Problems,' But Zscaler Is A 'Good One' To Buy

    Get the next $ACVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACVA
    $ALTI
    $AMD
    $AMLX

    CompanyDatePrice TargetRatingAnalyst
    Amylyx Pharmaceuticals Inc.
    $AMLX
    3/3/2026$21.00Buy
    Stifel
    Quanta Services Inc.
    $PWR
    3/2/2026$425.00 → $570.00Buy
    TD Cowen
    Synopsys Inc.
    $SNPS
    2/27/2026$480.00Overweight → Equal-Weight
    Morgan Stanley
    Installed Building Products Inc.
    $IBP
    2/27/2026$326.00Sell → Hold
    Vertical Research
    Lantheus Holdings Inc.
    $LNTH
    2/26/2026Mkt Perform → Outperform
    William Blair
    ACV Auctions Inc.
    $ACVA
    2/24/2026Mkt Perform → Outperform
    Barrington Research
    ACV Auctions Inc.
    $ACVA
    2/24/2026$7.00Buy → Neutral
    Citigroup
    ICON plc
    $ICLR
    2/23/2026$135.00Hold → Buy
    Jefferies
    More analyst ratings

    $ACVA
    $ALTI
    $AMD
    $AMLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Sales Officer Waterman Michael bought $1,000,036 worth of shares (214,600 units at $4.66), increasing direct ownership by 61% to 569,102 units (SEC Form 4)

    4 - ACV Auctions Inc. (0001637873) (Issuer)

    3/2/26 4:25:53 PM ET
    $ACVA
    Real Estate

    Director Lindstrom Richard L Md bought $461,354 worth of shares (60,229 units at $7.66), increasing direct ownership by 32% to 246,933 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/24/26 6:13:03 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Chamoun George bought $123,312 worth of shares (16,892 units at $7.30), increasing direct ownership by 0.58% to 2,928,705 units (SEC Form 4)

    4 - ACV Auctions Inc. (0001637873) (Issuer)

    2/10/26 4:48:21 PM ET
    $ACVA
    Real Estate

    $ACVA
    $ALTI
    $AMD
    $AMLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Amylyx Pharmaceuticals with a new price target

    Stifel initiated coverage of Amylyx Pharmaceuticals with a rating of Buy and set a new price target of $21.00

    3/3/26 8:26:33 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen reiterated coverage on Quanta Services with a new price target

    TD Cowen reiterated coverage of Quanta Services with a rating of Buy and set a new price target of $570.00 from $425.00 previously

    3/2/26 8:10:51 AM ET
    $PWR
    Engineering & Construction
    Industrials

    Synopsys downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Synopsys from Overweight to Equal-Weight and set a new price target of $480.00

    2/27/26 8:29:50 AM ET
    $SNPS
    Computer Software: Prepackaged Software
    Technology

    $ACVA
    $ALTI
    $AMD
    $AMLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, CEO and Chairman Edwards Jeffrey W. sold $125,624,000 worth of shares (400,000 units at $314.06) (SEC Form 4)

    4 - Installed Building Products, Inc. (0001580905) (Issuer)

    3/4/26 4:38:00 PM ET
    $IBP
    Homebuilding
    Consumer Discretionary

    Officer Niedzwiecki Daniel was granted 5,169 shares and covered exercise/tax liability with 8,259 shares, decreasing direct ownership by 4% to 83,967 units (SEC Form 4)

    4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

    3/4/26 4:19:46 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Commercial Officer Morgan Amanda Michelle covered exercise/tax liability with 3,336 shares and was granted 2,782 shares, decreasing direct ownership by 1% to 38,540 units (SEC Form 4)

    4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

    3/4/26 4:19:29 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACVA
    $ALTI
    $AMD
    $AMLX
    SEC Filings

    View All

    SEC Form 144 filed by Remitly Global Inc.

    144 - Remitly Global, Inc. (0001782170) (Subject)

    3/4/26 4:44:08 PM ET
    $RELY
    Real Estate

    SEC Form 8-K filed by Quanta Services Inc.

    8-K - QUANTA SERVICES, INC. (0001050915) (Filer)

    3/4/26 4:30:18 PM ET
    $PWR
    Engineering & Construction
    Industrials

    SEC Form 144 filed by Advanced Micro Devices Inc.

    144 - ADVANCED MICRO DEVICES INC (0000002488) (Subject)

    3/4/26 4:27:23 PM ET
    $AMD
    Semiconductors
    Technology

    $ACVA
    $ALTI
    $AMD
    $AMLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AI-Scale Ethernet at the Heart of Ethernet Alliance's OFC 2026 Demo

    BEAVERTON, OR, March 03, 2026 (GLOBE NEWSWIRE) -- The Ethernet Alliance, a global consortium dedicated to the continued success and advancement of Ethernet technologies, today revealed details of its interoperability demo taking place at the 2026 Optical Fiber Communication Conference and Exhibition (OFC 2026). The interactive display in booth 5023 illuminates how Ethernet continues to evolve to support AI workloads, hyperscale data center growth, and emerging network architectures operating at terabit speeds. The OFC 2026 expo will be held March 17–19, 2026 at the Los Angeles Convention Center, in Los Angeles, Calif. "With networks rapidly scaling to meet the demands of AI, cloud inf

    3/3/26 10:02:00 AM ET
    $ANET
    $APH
    $CSCO
    Computer Communications Equipment
    Telecommunications
    Electrical Products
    Technology

    CELEBRITY CRUISES RELAUNCHES CELEBRITY SOLSTICE WITH EIGHT NEW EXPERIENCES

    The renewed Celebrity Solstice departed Singapore on March 2, 2026, with eight new experiences - including four brand-new spaces, and will set sail in Alaska this summer. MIAMI, March 3, 2026 /PRNewswire/ -- Celebrity Cruises' revitalized Celebrity Solstice set sail from Singapore on March 2, unveiling eight new experiences, including four spaces that are new to Celebrity – Trattoria Rossa, Sunset Park, The Parlor, and Boulevard Lounge – marking the beginning of the cruise line's major revitalization of its Solstice Series ships. Bow-to-stern enhancements also include refreshed accommodations – with updates to all existing staterooms, plus an additional 54 staterooms and four new stateroom c

    3/3/26 9:42:00 AM ET
    $RCL
    Marine Transportation
    Consumer Discretionary

    DigitalOcean Powers Workato's Agentic Enterprise with Production-scale AI

    Workato's AI Research Lab achieves 67% higher throughput, 77% faster time-to-first-token, and 67% lower inference costs on DigitalOcean's Agentic Inference Cloud, powered by NVIDIA DigitalOcean (NYSE:DOCN), the Agentic Inference Cloud built for production AI, today announced that Workato's AI Research Lab is using its vertically integrated, inference-optimized platform, accelerated by NVIDIA Hopper GPUs, to advance the development of its next-generation enterprise AI agents while materially improving performance, cost efficiency, and deployment speed. After moving its AI Labs workloads to DigitalOcean, Workato achieved immediate gains for frontier models, including Llama-3.3-70B: Inf

    3/3/26 9:00:00 AM ET
    $DOCN
    Computer Software: Programming Data Processing
    Technology

    $ACVA
    $ALTI
    $AMD
    $AMLX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    October 3, 2023 - FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants

    For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO

    10/3/23 2:56:27 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ACVA
    $ALTI
    $AMD
    $AMLX
    Leadership Updates

    Live Leadership Updates

    View All

    FTI Consulting Bolsters Mining Sector Expertise in Australia with Addition of Carrie Grimes

    SYDNEY, March 02, 2026 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE:FCN) today announced the appointment of Carrie Grimes as a Senior Managing Director in the Business Transformation – Mining practice within the firm's Corporate Finance segment in Australia. Ms. Grimes, who is based in Brisbane, joins with more than 20 years of experience as a trusted advisor working with organisations to define and deliver strategic transformation programs that respond to global trends and drive a competitive edge. Ms. Grimes' experience includes working with global clients in the mining, oil and gas, utilities, and infrastructure industries, with a particular focus on operational improvement, aligning

    3/2/26 4:30:00 PM ET
    $FCN
    Professional Services
    Consumer Discretionary

    Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

    2/23/26 4:01:00 PM ET
    $MRNA
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Synopsys Appoints Former Deloitte Executive Peter Shimer to Board of Directors and Announces Board Transitions

    SUNNYVALE, Calif., Feb. 19, 2026 /PRNewswire/ -- Synopsys, Inc. (NASDAQ:SNPS) today announced the appointment of Peter A. Shimer to its board of directors. Shimer brings four decades of experience at international public accounting firm Deloitte where he held numerous executive roles, including serving as its interim chief executive officer (CEO). During his tenure on the Deloitte executive committee and under his financial stewardship, the firm increased annual revenue by more than 135% to $30 billion. Shimer's appointment is effective immediately, and he will serve on the board's audit committee.

    2/19/26 4:01:00 PM ET
    $SNPS
    Computer Software: Prepackaged Software
    Technology

    $ACVA
    $ALTI
    $AMD
    $AMLX
    Financials

    Live finance-specific insights

    View All

    Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Recruitment of the pivotal Phase 3 LUCIDITY trial of avexitide in PBH is complete; continue to expect to randomize and dose last eligible participants in Q1 2026, with topline data anticipated in Q3 2026 Cash runway expected to fund operations through potential avexitide commercialization and into 2028 Management to host conference call and webcast today at 8:00 a.m. Eastern Time Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today reported financial and business results for the fourth quarter and full year ended December 31, 2025. "2025 was a year of meaningful advancement for Amylyx's pivotal avexitide program in post-bariatric hypoglycemia, as well as

    3/3/26 7:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dell Technologies Declares Quarterly Cash Dividend

    Dell Technologies (NYSE:DELL) announces that its board of directors has declared a quarterly cash dividend of $0.63 per common share, which will be payable on May 1 to shareholders of record as of Apr. 21. About Dell Technologies Dell Technologies (NYSE:DELL) helps organizations and individuals build their digital future and transform how they work, live and play. The company provides customers with the industry's broadest and most innovative technology and services portfolio for the AI era. Copyright © 2026 Dell Inc. or its subsidiaries. All Rights Reserved. Dell Technologies, Dell, EMC and Dell EMC are trademarks of Dell Inc. or its subsidiaries. Other trademarks may be trademarks o

    3/2/26 8:30:00 AM ET
    $DELL
    Computer Manufacturing
    Technology

    Dell Technologies Delivers Fourth Quarter and Full-Year Fiscal 2026 Results

    Dell Technologies (NYSE:DELL) announces financial results for its fiscal 2026 fourth quarter and full year ended January 30, 2026. The company also provides guidance for its fiscal 2027 first quarter and full year. Full-Year Summary Record full-year revenue of $113.5 billion, up 19% year over year Record full-year diluted earnings per share (EPS) of $8.68, up 36% year over year, and record full-year non-GAAP diluted EPS of $10.30, up 27% Record full-year cash flow from operations of $11.2 billion Announcing a cash dividend increase of 20% and $10 billion increase in share repurchase authorization FY27 guidance: Full-year revenue growth of 23% at the midpoint, diluted EPS gr

    2/26/26 4:05:00 PM ET
    $DELL
    Computer Manufacturing
    Technology

    $ACVA
    $ALTI
    $AMD
    $AMLX
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Stock Movement: Insider Purchase at AlTi Global Inc. on Jun 5

    On June 5, 2024, **Tiedemann Michael** made a significant purchase of **47,373** units of **AlTi Global Inc.** shares at a price of **$4.86** per share, amounting to a total investment of **$230,460**. This transaction led to a **10%** increase in his direct ownership of the company's shares, bringing his total holding to **499,887** units. This insider purchase was disclosed in the **SEC Form 4** filing. Interestingly, this purchase follows a series of other notable transactions by **Tiedemann Michael** in the past month. On May 21, 2024, he acquired **100,000** units of shares at **$4.61** each, increasing his direct ownership by **32%** to **409,146** units. Just two days later, on May 23

    6/10/24 1:07:48 AM ET
    $ALTI
    Investment Managers
    Finance

    $ACVA
    $ALTI
    $AMD
    $AMLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Indivior PLC

    SC 13G - INDIVIOR PLC (0001625297) (Subject)

    11/15/24 6:03:54 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Lantheus Holdings Inc.

    SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)

    11/14/24 8:21:14 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

    SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    11/14/24 5:49:38 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care